Several studies looked at bone mineral density, which is a measurement of bone strength, in HIV+ people. One study examined 272 women (both HIV+ and HIV-negative) and found that HIV+ women ware 3 times more likely to have decreased bone strength (abstract 744). This loss in bone strength can lead to serious bone fractures, such as hip fractures, that can result in an extended hospital stay and the need for physical therapy. In addition, this condition may even lead to fragility fractures. These types of fractures can occur with little or no trauma. According to another study presented at the conference, patients who have fragility fractures commonly have more serious bone fractures later (abstract 743). The affects of Fosamax (alendronate) in treating this loss of bone strength was tested in an "open-label" study, meaning that patients knew which treatment they were receiving (abstract 742). Forty-one HIV+ men and women ware randomly assigned (by chance, like flipping a coin) to receive Fosamax combined with calcium and vitamin D supplements or just calcium and vitamin D supplements. Fosamax had no effect on increasing bone mineral density, but had other beneficial effects.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||11th Retrovirus Conference Highlights; measurement of bone strength|
|Publication:||HIV Treatment: ALERTS!|
|Article Type:||Brief Article|
|Date:||Jun 1, 2004|
|Previous Article:||Obesity epidemic.|
|Next Article:||Diabetes risks.|